Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Gross Margin: 2020-2025

Historic Gross Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to 13.58%.

  • Maravai Lifesciences Holdings' Gross Margin fell 3312.00% to 13.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.07%, marking a year-over-year decrease of 2516.00%. This contributed to the annual value of 41.79% for FY2024, which is 673.00% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its Gross Margin stood at 13.58% for Q3 2025, which was down 17.12% from 16.39% recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Gross Margin high stood at 84.55% for Q2 2022, and its period low was 13.58% during Q3 2025.
  • In the last 3 years, Maravai Lifesciences Holdings' Gross Margin had a median value of 40.27% in 2024 and averaged 36.77%.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Gross Margin spiked by 2,783bps in 2021, and later crashed by 4,735bps in 2023.
  • Quarterly analysis of 5 years shows Maravai Lifesciences Holdings' Gross Margin stood at 82.87% in 2021, then slumped by 888bps to 73.99% in 2022, then slumped by 2,134bps to 52.65% in 2023, then plummeted by 1,836bps to 34.28% in 2024, then crashed by 3,312bps to 13.58% in 2025.
  • Its Gross Margin stands at 13.58% for Q3 2025, versus 16.39% for Q2 2025 and 16.49% for Q1 2025.